Unknown

Dataset Information

0

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

ABSTRACT:

SUBMITTER: Ikeda R 

PROVIDER: S-EPMC10909146 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Treatment-emergent neuroendocrine prostate cancer with a germline <i>BRCA2</i> mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
| S-EPMC7903888 | biostudies-literature
Unknown Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
| S-EPMC6884546 | biostudies-literature
Unknown Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
| S-EPMC2948551 | biostudies-literature
Unknown Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.
| S-EPMC7675892 | biostudies-literature
Unknown The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
| S-EPMC11570197 | biostudies-literature
Unknown Germline <i>BRCA2</i> mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy.
| S-EPMC8788613 | biostudies-literature
Unknown Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
| S-EPMC6057749 | biostudies-literature
Unknown Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
| S-EPMC6938600 | biostudies-literature
Unknown Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
| S-EPMC8154637 | biostudies-literature
Unknown An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
| S-EPMC7068944 | biostudies-literature